• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

基于微小RNA的细胞重编程与紫杉醇联合应用可增强复发性和多药耐药性上皮性卵巢癌模型的治疗效果。

Combination microRNA-based cellular reprogramming with paclitaxel enhances therapeutic efficacy in a relapsed and multidrug-resistant model of epithelial ovarian cancer.

作者信息

Gandham Srujan K, Rao Mounika, Shah Aayushi, Trivedi Malav S, Amiji Mansoor M

机构信息

Department of Pharmaceutical Sciences, School of Pharmacy, Northeastern University, Boston, MA 02115, USA.

Department of Pharmaceutical Sciences, College of Pharmacy, Nova Southeastern University, Fort Lauderdale, FL 33314, USA.

出版信息

Mol Ther Oncolytics. 2022 Mar 15;25:57-68. doi: 10.1016/j.omto.2022.03.005. eCollection 2022 Jun 16.

DOI:10.1016/j.omto.2022.03.005
PMID:35399604
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8971728/
Abstract

Most advanced-stage ovarian cancer patients, including those with epithelial ovarian cancer (EOC), develop recurrent disease and acquisition of resistance to chemotherapy, leading to limited treatment options. Decrease in Let7b miRNA levels in clinical ovarian cancer has been associated with chemoresistance, increased proliferation, invasion, and relapse in EOC. We have established a murine EOC relapsed model by administering paclitaxel (PTX) and stopping therapy to allow for tumor regrowth. Global microRNA profiling in the relapsed tumor showed significant downregulation of Let7b relative to untreated tumors. Here, we report the use of hyaluronic acid (HA)-based nanoparticle formulation that can deliver Let7b miRNA mimic to tumor cells and achieve cellular programming both and . We demonstrate that a therapeutic combination of Let7b miRNA and PTX leads to significant improvement in anti-tumor efficacy in the relapsed model of EOC. We further demonstrate that the combination therapy is safe for repeated administration. This novel approach of cellular reprogramming of tumor cells using clinically relevant miRNA mimic in combination with chemotherapy could enable more effective therapeutic outcomes for patients with advanced-stage relapsed EOC.

摘要

大多数晚期卵巢癌患者,包括上皮性卵巢癌(EOC)患者,都会出现疾病复发并对化疗产生耐药性,导致治疗选择有限。临床卵巢癌中Let7b微小RNA水平的降低与EOC中的化疗耐药、增殖增加、侵袭和复发有关。我们通过给予紫杉醇(PTX)然后停止治疗以允许肿瘤重新生长,建立了一种小鼠EOC复发模型。复发肿瘤中的全局微小RNA谱分析显示,与未治疗的肿瘤相比,Let7b显著下调。在此,我们报告了一种基于透明质酸(HA)的纳米颗粒制剂的应用,该制剂可以将Let7b微小RNA模拟物递送至肿瘤细胞,并在体内和体外实现细胞编程。我们证明,Let7b微小RNA与PTX的联合治疗可使EOC复发模型中的抗肿瘤疗效得到显著改善。我们进一步证明,联合治疗重复给药是安全的。这种使用临床相关微小RNA模拟物与化疗相结合对肿瘤细胞进行细胞重编程的新方法,可为晚期复发EOC患者带来更有效的治疗效果。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7ec0/8971728/8a13e18fa660/gr5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7ec0/8971728/e06a1df25a19/fx1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7ec0/8971728/29978565cd10/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7ec0/8971728/900960a97131/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7ec0/8971728/ee7245b4a73b/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7ec0/8971728/c323f3b9dd02/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7ec0/8971728/8a13e18fa660/gr5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7ec0/8971728/e06a1df25a19/fx1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7ec0/8971728/29978565cd10/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7ec0/8971728/900960a97131/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7ec0/8971728/ee7245b4a73b/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7ec0/8971728/c323f3b9dd02/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7ec0/8971728/8a13e18fa660/gr5.jpg

相似文献

1
Combination microRNA-based cellular reprogramming with paclitaxel enhances therapeutic efficacy in a relapsed and multidrug-resistant model of epithelial ovarian cancer.基于微小RNA的细胞重编程与紫杉醇联合应用可增强复发性和多药耐药性上皮性卵巢癌模型的治疗效果。
Mol Ther Oncolytics. 2022 Mar 15;25:57-68. doi: 10.1016/j.omto.2022.03.005. eCollection 2022 Jun 16.
2
Expert consensus: Profiling and management of advanced or metastatic epithelial ovarian cancer.专家共识:晚期或转移性上皮性卵巢癌的评估和管理。
Rev Colomb Obstet Ginecol. 2024 Jun 14;75(1):4094. doi: 10.18597/rcog.4094.
3
Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer.聚乙二醇脂质体阿霉素治疗复发性上皮性卵巢癌。
Cochrane Database Syst Rev. 2023 Jul 5;7(7):CD006910. doi: 10.1002/14651858.CD006910.pub3.
4
Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer.聚乙二醇化脂质体阿霉素用于复发性上皮性卵巢癌
Cochrane Database Syst Rev. 2013 Jul 9;2013(7):CD006910. doi: 10.1002/14651858.CD006910.pub2.
5
A novel targeted co-delivery nanosystem for enhanced ovarian cancer treatment via multidrug resistance reversion and mTOR-mediated signaling pathway.一种新型靶向共递纳米系统,通过多药耐药逆转和 mTOR 介导的信号通路增强卵巢癌治疗。
J Nanobiotechnology. 2021 Dec 23;19(1):444. doi: 10.1186/s12951-021-01139-1.
6
CD44-Targeting PLGA Nanoparticles Incorporating Paclitaxel and FAK siRNA Overcome Chemoresistance in Epithelial Ovarian Cancer.载紫杉醇和 FAK siRNA 的靶向 CD44 的 PLGA 纳米粒克服上皮性卵巢癌的化疗耐药性。
Cancer Res. 2018 Nov 1;78(21):6247-6256. doi: 10.1158/0008-5472.CAN-17-3871. Epub 2018 Aug 16.
7
Role of hsa‑miR‑105 during the pathogenesis of paclitaxel resistance and its clinical implication in ovarian cancer.hsa-miR-105 在紫杉醇耐药发病机制中的作用及其在卵巢癌中的临床意义。
Oncol Rep. 2021 May;45(5). doi: 10.3892/or.2021.8035. Epub 2021 Apr 13.
8
Ovarian cancer targeted hyaluronic acid-based nanoparticle system for paclitaxel delivery to overcome drug resistance.用于紫杉醇递送以克服耐药性的卵巢癌靶向透明质酸纳米粒子系统。
Drug Deliv. 2016 Jun;23(5):1810-7. doi: 10.3109/10717544.2015.1101792. Epub 2015 Nov 4.
9
Ultrasound-Mediated Long-Circulating Nanopolymer Delivery of Therapeutic siRNA and Antisense MicroRNAs Leads to Enhanced Paclitaxel Sensitivity in Epithelial Ovarian Cancer Chemotherapy.超声介导的治疗性小干扰RNA和反义微小RNA的长循环纳米聚合物递送可增强上皮性卵巢癌化疗中对紫杉醇的敏感性。
ACS Biomater Sci Eng. 2020 Jul 13;6(7):4036-4050. doi: 10.1021/acsbiomaterials.0c00330. Epub 2020 Jun 3.
10
Mathematical Modeling and Experimental Validation of Extracellular Vesicle-Mediated Tumor Suppressor MicroRNA Delivery and Propagation in Ovarian Cancer Cells.细胞外囊泡介导的肿瘤抑制 microRNA 递呈和在卵巢癌细胞中传播的数学建模和实验验证。
Mol Pharm. 2022 Nov 7;19(11):4067-4079. doi: 10.1021/acs.molpharmaceut.2c00525. Epub 2022 Oct 13.

引用本文的文献

1
Long Non-Coding, Micro, and Circular RNAs in Ovarian Cancer Metastasis: Pathways and Treatment Approaches.长链非编码RNA、微小RNA和环状RNA在卵巢癌转移中的作用:途径与治疗方法
Reprod Sci. 2025 Aug 15. doi: 10.1007/s43032-025-01948-x.
2
Research progress and treatment status of malignant ascites.恶性腹水的研究进展与治疗现状
Front Oncol. 2024 Dec 16;14:1390426. doi: 10.3389/fonc.2024.1390426. eCollection 2024.
3
STK33 as the functional substrate of miR-454-3p for suppression and apoptosis in neuroblastoma.STK33作为miR-454-3p在神经母细胞瘤中发挥抑制和凋亡作用的功能性底物。

本文引用的文献

1
Preparation of Hyaluronic Acid-Based Nanoparticles for Macrophage-Targeted MicroRNA Delivery and Transfection.基于透明质酸的纳米颗粒用于巨噬细胞靶向 microRNA 递呈和转染的制备。
Methods Mol Biol. 2020;2118:99-110. doi: 10.1007/978-1-0716-0319-2_7.
2
Hydrophobically Modified let-7b miRNA Enhances Biodistribution to NSCLC and Downregulates HMGA2 In Vivo.疏水修饰的let-7b微小RNA增强对非小细胞肺癌的生物分布并在体内下调HMGA2
Mol Ther Nucleic Acids. 2020 Mar 6;19:267-277. doi: 10.1016/j.omtn.2019.11.008. Epub 2019 Nov 18.
3
Let-7 as biomarker, prognostic indicator, and therapy for precision medicine in cancer.
Mol Cells. 2024 Dec;47(12):100145. doi: 10.1016/j.mocell.2024.100145. Epub 2024 Nov 6.
4
MicroRNA‑mediated approaches in ovarian cancer therapy: A comprehensive systematic review.微小RNA介导的卵巢癌治疗方法:一项全面的系统综述。
Oncol Lett. 2024 Aug 12;28(4):491. doi: 10.3892/ol.2024.14624. eCollection 2024 Oct.
5
The CD47/TSP-1 axis: a promising avenue for ovarian cancer treatment and biomarker research.CD47/TSP-1 轴:卵巢癌治疗和生物标志物研究的有前途途径。
Mol Cancer. 2024 Aug 14;23(1):166. doi: 10.1186/s12943-024-02073-0.
6
MiR-223-3p in Cancer Development and Cancer Drug Resistance: Same Coin, Different Faces.miR-223-3p 在癌症发生发展和癌症药物耐药中的作用:同一枚硬币,两面不同。
Int J Mol Sci. 2024 Jul 26;25(15):8191. doi: 10.3390/ijms25158191.
7
Transcriptome profiling and characterization of peritoneal metastasis ovarian cancer xenografts in humanized mice.人源化小鼠腹膜转移卵巢癌异种移植的转录组谱分析和特征描述。
Sci Rep. 2024 May 24;14(1):11894. doi: 10.1038/s41598-024-60501-z.
8
Current strategies for early epithelial ovarian cancer detection using miRNA as a potential tool.使用微小RNA(miRNA)作为潜在工具进行早期上皮性卵巢癌检测的当前策略。
Front Mol Biosci. 2024 Apr 16;11:1361601. doi: 10.3389/fmolb.2024.1361601. eCollection 2024.
9
Development and Perspectives: Multifunctional Nucleic Acid Nanomedicines for Treatment of Gynecological Cancers.发展与展望:用于治疗妇科癌症的多功能核酸纳米药物。
Small. 2024 Oct;20(41):e2301776. doi: 10.1002/smll.202301776. Epub 2023 Jul 30.
10
Engineering of inhalable nano-in-microparticles for co-delivery of small molecules and miRNAs.用于小分子和微小RNA共递送的可吸入纳米微颗粒工程
Discov Nano. 2023 Mar 10;18(1):38. doi: 10.1186/s11671-023-03781-0.
Let-7作为癌症精准医学中的生物标志物、预后指标及治疗手段。
Clin Transl Med. 2019 Aug 28;8(1):24. doi: 10.1186/s40169-019-0240-y.
4
Improved anti-tumor efficacy of paclitaxel in combination with MicroRNA-125b-based tumor-associated macrophage repolarization in epithelial ovarian cancer.紫杉醇联合 MicroRNA-125b 重极化肿瘤相关巨噬细胞增强上皮性卵巢癌的抗肿瘤疗效。
Cancer Lett. 2019 Oct 1;461:1-9. doi: 10.1016/j.canlet.2019.07.002. Epub 2019 Jul 6.
5
miR-205 regulates the proliferation and invasion of ovarian cancer cells via suppressing PTEN/SMAD4 expression.微小RNA-205通过抑制PTEN/SMAD4的表达来调控卵巢癌细胞的增殖和侵袭。
Oncol Lett. 2018 May;15(5):7571-7578. doi: 10.3892/ol.2018.8313. Epub 2018 Mar 21.
6
Repolarization of Tumor-Associated Macrophages in a Genetically Engineered Nonsmall Cell Lung Cancer Model by Intraperitoneal Administration of Hyaluronic Acid-Based Nanoparticles Encapsulating MicroRNA-125b.基于透明质酸的纳米颗粒包载 microRNA-125b 经腹腔给药调控肿瘤相关巨噬细胞再极化在基因工程非小细胞肺癌模型中的作用
Nano Lett. 2018 Jun 13;18(6):3571-3579. doi: 10.1021/acs.nanolett.8b00689. Epub 2018 May 7.
7
Revisiting the role of ABC transporters in multidrug-resistant cancer.重新审视 ABC 转运蛋白在多药耐药性癌症中的作用。
Nat Rev Cancer. 2018 Jul;18(7):452-464. doi: 10.1038/s41568-018-0005-8.
8
miR-148a-3p suppresses epithelial ovarian cancer progression primarily by targeting c-Met.微小RNA-148a-3p主要通过靶向c-Met抑制上皮性卵巢癌进展。
Oncol Lett. 2018 May;15(5):6131-6136. doi: 10.3892/ol.2018.8110. Epub 2018 Feb 23.
9
Biomarker potential of IL-6 and VEGF-A in ascitic fluid of epithelial ovarian cancer patients.白细胞介素 6 和血管内皮生长因子 A 在卵巢癌患者腹水中的标志物潜力。
Clin Chim Acta. 2018 Jul;482:27-32. doi: 10.1016/j.cca.2018.03.019. Epub 2018 Mar 20.
10
Potential microRNA-related Targets for Therapeutic Intervention with Ovarian Cancer Metastasis.用于卵巢癌转移治疗干预的潜在微小RNA相关靶点
Cancer Genomics Proteomics. 2018 Jan-Feb;15(1):1-15. doi: 10.21873/cgp.20061.